Literature DB >> 14976159

The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases.

Andrew Singleton1, Amanda Myers, John Hardy.   

Abstract

Loci underlying autosomal dominant forms of most neurodegenerative disease have been identified: prion mutations cause Gerstmann Straussler syndrome and hereditary Creuzfeldt-Jakob disease, tau mutations cause autosomal dominant frontal temporal dementia, and alpha-synuclein mutations cause autosomal dominant Parkinson's disease. In all these cases, the pathogenic mutation is in the protein that is deposited in the diseased tissue and in these cases the whole protein is deposited. In Alzheimer's disease, mutations in APP or presenilin 1 or 2 cause autosomal dominant disease and these are the substrate and proteases, respectively, which are responsible for the production of the deposited peptide, Abeta. Thus, in all cases, the mutations lead to the disease by a mechanism that involves the deposition process. We briefly review this remarkably predictable biology, but also point out that it seems sporadic forms of all these diseases are predisposed to by genetic variability at the same loci, strongly suggesting that the quantity of the normal protein produced influences risk for the sporadic forms of the disease. The evidence for this assertion is strongest in Parkinson's disease (PD), where genetic variability in alpha-synuclein expression affects risk of developing disease, although the oldest evidence for the notion that increased expression of normal sequence protein can lead to disease comes from the observation of Alzheimer's disease in trisomy 21 cases. From these observations, we make predictions concerning the etiology and pathogenesis of neurodegenerative diseases in general.

Entities:  

Mesh:

Year:  2004        PMID: 14976159     DOI: 10.1093/hmg/ddh093

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

1.  Sedimentation velocity studies of the high-molecular weight aggregates of the HIV gp41 ectodomain.

Authors:  Amy Jacobs; Kari Hartman; Thomas Laue; Michael Caffrey
Journal:  Protein Sci       Date:  2004-08-31       Impact factor: 6.725

2.  Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study.

Authors:  C Vollmert; O Windl; W Xiang; A Rosenberger; I Zerr; H-E Wichmann; H Bickeböller; T Illig; H A Kretzschmar
Journal:  J Med Genet       Date:  2006-10       Impact factor: 6.318

3.  Tau isoform composition influences rate and extent of filament formation.

Authors:  Qi Zhong; Erin E Congdon; Haikady N Nagaraja; Jeff Kuret
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

4.  Translational gene mapping of cognitive decline.

Authors:  Beth Wilmot; Shannon K McWeeney; Randal R Nixon; Thomas J Montine; Jamie Laut; Christina A Harrington; Jeffrey A Kaye; Patricia L Kramer
Journal:  Neurobiol Aging       Date:  2006-12-14       Impact factor: 4.673

5.  The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging.

Authors:  William K Gottschalk; Michael W Lutz; Yu Ting He; Ann M Saunders; Daniel K Burns; Allen D Roses; Ornit Chiba-Falek
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-11

6.  The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes.

Authors:  Colton Linnertz; Lauren Anderson; William Gottschalk; Donna Crenshaw; Michael W Lutz; Jawara Allen; Sunita Saith; Mirta Mihovilovic; James R Burke; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Alzheimers Dement       Date:  2014-01-15       Impact factor: 21.566

Review 7.  Genetic analysis of pathways to Parkinson disease.

Authors:  John Hardy
Journal:  Neuron       Date:  2010-10-21       Impact factor: 17.173

8.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

9.  The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair.

Authors:  Emmette R Hutchison; Eitan Okun; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

10.  Expression variation: its relevance to emergence of chronic disease and to therapy.

Authors:  Anatoly L Mayburd
Journal:  PLoS One       Date:  2009-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.